Trial
NCT03222401
Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Alopexx Pharmaceuticals, LLC
Collaborators
—
Condition
Neisseria Gonorrhoeae
Intervention
1 mg/kg single infusion of F598
Why stopped
Interim analysis suggested that the trial, as designed, was not adequately powered to detect a therapeutic effect.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-02-08